Related Experiment Video
Updated: May 24, 2026
11:12
Nondestructive Monitoring of Degradable Scaffold-Based Tissue-Engineered Blood Vessel Development Using Optical Coherence Tomography
Published on: October 3, 2018
Everolimus-eluting ABSORB bioresorbable vascular scaffold: present and future perspectives
Salvatore Brugaletta1, Hector M Garcia-Garcia, Yoshinobu Onuma
1Thoraxcenter, Erasmus MC, Thoraxcenter, Gravendijkwal, 2303015 CE, Rotterdam, The Netherlands.
Expert Review of Medical Devices
|March 17, 2012
Summary
Bioresorbable vascular scaffolds offer transient support and drug delivery, avoiding metallic stent limitations. Early studies show promising outcomes, with potential for vessel recovery and normal function.
Area of Science:
- Cardiovascular medicine
- Biomaterials science
- Interventional cardiology
Background:
- Metallic drug-eluting stents (DESs) have long-term limitations.
- Bioresorbable vascular scaffolds (BVS) offer transient support and drug delivery.
- BVS technology aims to overcome DES safety concerns and improve clinical outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of the everolimus-eluting ABSORB bioresorbable vascular scaffold.
- To compare the ABSORB scaffold with the Xience Prime metallic stent in a broad patient population.
Main Methods:
- First clinical studies involved a small patient cohort.
- A randomized trial comparing ABSORB with Xience Prime stent is underway.
- Follow-up extends up to 5 years.
Main Results:
- Early clinical studies demonstrated promising results with good clinical outcomes.
- Scaffolded segments showed significant morphological and functional modifications.
- Observed benefits include late lumen enlargement and recuperation of normal vasoreactivity.
Conclusions:
- Everolimus-eluting ABSORB scaffolds provide transient vessel support and drug delivery.
- BVS technology eliminates the permanent caging associated with metallic DESs.
- Further randomized trials are necessary to confirm efficacy and safety in a wider population.
